GlassScriptPhysician profile
Jessica Covington
NPI 1134762750
$846.80
in general payments reported to CMS, 2019-2025
20 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $132 · 2024: $309 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $110.20 | 2024-2025 | |
| Novo Nordisk INC | $101.48 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Corium, LLC | $81.02 | 2024-2025 | Azstarys |
| Abbvie INC. | $77.15 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $60.43 | 2025 | Tlando |
| Astrazeneca Pharmaceuticals LP | $48.34 | 2024-2025 | Farxiga, Breztri |
| Grifols USA, LLC | $47.88 | 2023 | Xembify |
| Tris Pharma INC | $42.22 | 2024-2025 | Dyanavel Xr |
| Exact Sciences Corporation | $34.37 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $34.01 | 2024-2025 | Mounjaro |
| Inspire Medical Systems, INC. | $27.23 | 2025 | Inspire |
| Boston Scientific Corporation | $27.17 | 2025 | Watchman Flx |
| Acella Pharmaceuticals, LLC | $25.83 | 2024 | NP Thyroid 60 |
| Supernus Pharmaceuticals, INC. | $24.58 | 2025 | Qelbree |
| Medtronic, INC. | $24.14 | 2025 | Inceptiv |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $18.36 | 2024 | Adzenys Xr-Odt |
| Tolmar, INC. | $18.32 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.30 | 2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.00 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $13.77 | 2023 | Verquvo, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.